\n\n\n\n\t\t\n\t\t\tIntradigm\n\t\t\thttp://www.intradigm.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tIntradigm\u2019s lead product candidate ICS-283 is a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathway. The product uses an RGD peptide as the ligand to target...More»
\n\t\t\tIntradigm\u2019s lead product candidate ICS-283 is a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathway. The product uses an RGD peptide as the ligand to target av-expressing endothelial cells. ICS-283 is currently in the preclinical stage. Data from several in vivo models including xenograft models of different cancers (colorectal, renal, head and neck, and breast) have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as a validated target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm systemic delivery of RNAi in man.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tPalo Alto, CA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\tbiotech,\n\t\t\t\tendothelial,\n\t\t\t\tintradigm,\n\t\t\t\tcells,\n\t\t\t\tgrowth,\n\t\t\t\tRNAi,\n\t\t\t\ttheraputic\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series B - $21.4M (01/2009)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tLilly Ventures,\n\t\t\t\t\t\n\t\tMP Healthcare Venture Management,\n\t\t\t\t\t\n\t\tFrazier Healthcare Ventures,\n\t\t\t\t\t\n\t\tAlta Partners,\n\t\t\t\t\t\n\t\tMediBic Alliance Technology Fund,\n\t\t\t\t\t\n\t\tNovartis Venture Fund,\n\t\t\t\t\t\n\t\tAstellas Venture Management\n\t\t\t\t
\n\t\t\tMarket
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tNanopoint\n\t\t\t\t
\n\t\t\tRecent News
\n\t\t\t\t\n\t\t\t\t\tJan 7, 2009\n\t\t\t\t\tIntradigm Closes $21.4M Round\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\tOct 2, 2008\n\t\t\t\t\tIntradigm Gets $18.5M In Series B\n\t\t\t\t
\n\t\t\t